PRESS RELEASE
ALIKO SCIENTIFIC (Ikonisys SA), through its fully owned Italian subsidiary Hospitex International,
Signs Exclusive Distribution Agreement for Italy with Menarini Diagnostics

Florence (Italy) and Paris (France), June 4, 2025 – 7:30 am CEST – ALIKO SCIENTIFIC (Ikonisys SA) Euronext
Growth: ALIKO, through its fully owned Italian subsidiary Hospitex International is pleased to announce the
signing of an exclusive distribution agreement with Menarini Diagnostics, the European largest distributor
in the field of pathology and IVD (in vitro diagnostics).

Under the terms of the agreement, Menarini Diagnostics will exclusively distribute, in the Italian market,
ALIKO SCIENTIFIC group’s product portfolio that includes FISH technology (manufactured in the USA by
Ikonisys) and Hospitex’s full range of cytology, cell-blocking and rapid immunohistochemistry products.

Menarini Diagnostics Italy, part of Menarini pharmaceutical group, is the European largest IVD distribution
player, with a track record and extensive experience in pathology.
The company already distributes products from leading global manufacturers in the sector. The addition of
the ALIKO SCIENTIFIC business lines will further enhance Menarini’s offering, complementing its current
histology solutions for anatomical pathology laboratories and thus achieving one of the most comprehensive
and integrated offers in the market.

Hospitex has estimated the addressable Italian market for cytology and cell block product lines at
approximately €28 million annually. Market forecasts for the FISH and immunohistochemistry segments will
be developed following market entry and the collection of relevant data. The Group’s goal is to capture a
significant share of the market within the first three years of commercial rollout.

Francesco Trisolini, CEO of Hospitex, commented: "This agreement with Menarini Diagnostics represents a
major milestone for the Group. By partnering with the largest European IVD distributor, we are confident that
our innovative solutions will reach a broader market and significantly improve diagnostic capabilities in
pathological anatomy. This agreement will also fuel our R&D programs to release new breakthrough
solutions for the cancer diagnostics market, such as FISH probes in a short timeframe."

Fabio Piazzalunga, Global Head of Diagnostics and General Manager of Menarini Diagnostics, added: "At
Menarini, we are deeply committed to advancing oncology diagnostics, and the addition of ALIKO
SCIENTIFIC’s cutting-edge technology to our portfolio aligns perfectly with our strategic vision. This
collaboration will allow us to offer a more comprehensive suite of solutions to pathology professionals across
Italy."




1
-----------------------

About ALIKO SCIENTIFIC (Ikonisys SA)
Headquartered in Paris, ALIKO SCIENTIFIC is the parent company of an international ecosystem of businesses dedicated to advancing
oncology diagnostics. Listed on Euronext Growth Paris under the ticker ALIKO, the company coordinates industrial, financial and
research activities through its subsidiaries: Ikonisys Inc. (USA) and Hospitex International (Italy). ALIKO SCIENTIFIC's mission is to
innovate cancer diagnosis by uniting cutting-edge technologies, resources, and strategic investments to create a global center of
excellence in oncology.
For more information, visit: www.alikoscientific.com

About IKONISYS
Ikonisys is a global leader in automated diagnostics, specializing in fluorescence in situ hybridization (FISH) and circulating tumor cell
(CTC) detection. Leveraging advanced artificial intelligence (AI) and a fully automated microscopy platform, Ikonisys provides
unmatched precision, scalability, and efficiency in cancer diagnostics and treatment monitoring. Recognized as pioneer in automation
for rare cell detection, Ikonisys is at the forefront of personalized medicine, empowering clinicians to deliver targeted therapies and
improve patient outcomes.
For more information, visit: www.ikonisys.com

About HOSPITEX
Hospitex, based in Florence, Italy, is a global leader in cytology innovation. The company conducts in-house research, development,
and production, thus ensuring the highest standards of quality. Hospitex offers the world's most advanced Liquid-Based Cytology
(LBC) technology, capable of processing any cytological sample with unmatched precision. Hospitex is uniquely positioned as the only
company fully prepared for seamless digital integration, paving the way for a transformative future in cytology diagnostics.
For more information, visit: www.hospitex.com




Contacts
Ikonisys NewCap NewCap
Alessandro Mauri Louis-Victor Delouvrier/Aurélie Manavarere Arthur Rouillé
CFO Investor Relations Media Relations
investors@ikonisys.com ikonisys@newcap.eu ikonisys@newcap.eu
Tel.: +33 (0)1 44 71 94 94 Tel.: +33 (0)1 44 71 00 15



Disclaimer
This press release contains forward-looking statements about the Company's prospects and development. These statements are
sometimes identified by the use of the future tense, the conditional tense and forward-looking words such as "believe", "aim to",
"expect", "intend", "estimate", "believe", "should", "could", "would" or "will" or, where appropriate, the negative of these terms or
any other similar variants or expressions. This information is not historical data and should not be construed as a guarantee that the
facts and data set forth will occur. This information is based on data, assumptions and estimates considered reasonable by the
Company. It is subject to change or modification due to uncertainties relating to the economic, financial, competitive and regulatory
environment. This information contains data relating to the Company's intentions, estimates and objectives concerning, in particular,
the market, strategy, growth, results, financial situation and cash flow of the Company. The forward-looking information contained in
this press release is made only as of the date of this press release. The Company does not undertake to update any forward-looking
information contained in this press release, except as required by applicable law or regulation. The Company operates in a competitive
and rapidly changing environment and therefore cannot anticipate all of the risks, uncertainties or other factors that may affect its
business, their potential impact on its business or the extent to which the materialization of any one risk or combination of risks could
cause results to differ materially from those expressed in any forward-looking information, it being recalled that none of this forward-
looking information constitutes a guarantee of actual results.




2